TWiV 730: COVID-19 clinical update #53 with Dr. Daniel Griffin

March 13, 2021

In COVID-19 clinical update #53, Daniel Griffin reviews underreporting of infections and long term disease in children, a blood test for T cells, results of phase 3 trials for monoclonal antibodies, preliminary findings on an oral antiviral, clinical trial of ivermectin, and recommendations for upcoming gatherings.

Hosts: Daniel Griffin and Vincent Racaniello

Click arrow to play
Download TWiV 730 (27 MB .mp3, 45 min)
Subscribe (free): iTunesGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

Leave a Reply

Your email address will not be published. Required fields are marked *

3 comments on “TWiV 730: COVID-19 clinical update #53 with Dr. Daniel Griffin

  1. John Wilkinson Mar 13, 2021

    Dr. Griffin, Why do you feel comfortable recommending J&Js single dose vaccine, but uncomfortable delaying the booster shot for other vaccines? Is there a fundamental difference in the immune response to the different vaccine types? The AZ Oxford vaccine is also an adenovirus vector vaccine but a booster shot is recommended for it. J&J are researching a second shot to see if it will improve efficacy. Surely partial suppression of the virus carries similar risks of propagating variants, regardless of which vaccine is used.

  2. richard moore MD Mar 14, 2021

    Dr Griffin please discuss outcome results with Dr Chesler.

  3. Jeffrey Fitzsimmons Mar 31, 2021

    Dr. Griffin, First, Thank you for your dedication to informing the public and your ongoing efforts to save lives. I had a question about the difference in acceptance between the mRNA vaccines and JnJ for example. Is there any reason to think there may be fewer side effects using the older (JNJ) type vaccines vs the newer mRNA ones? Thanks,